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AbstrACt
Objective Anonymised patient-level data from clinical 
research are increasingly recognised as a fundamental 
and valuable resource. It has value beyond the original 
research project and can help drive scientific research 
and innovations and improve patient care. To support 
responsible data sharing, we need to develop systems that 
work for all stakeholders. The members of the Independent 
Review Panel (IRP) for the data sharing platform Clinical 
Study Data Request (CSDR) describe here some summary 
metrics from the platform and challenge the research 
community on why the promised demand for data has not 
been observed.
summary of data From 2014 to the end of January 
2019, there were a total of 473 research proposals (RPs) 
submitted to CSDR. Of these, 364 met initial administrative 
and data availability checks, and the IRP approved 291. Of 
the 90 research teams that had completed their analyses 
by January 2018, 41 reported at least one resulting 
publication to CSDR. Less than half of the studies ever 
listed on CSDR have been requested.
Conclusion While acknowledging there are areas for 
improvement in speed of access and promotion of the 
platform, the total number of applications for access and 
the resulting publications have been low and challenge the 
sustainability of this model. What are the barriers for data 
contributors and secondary analysis researchers? If this 
model does not work for all, what needs to be changed? 
One thing is clear: that data access can realise new and 
unforeseen contributions to knowledge and improve 
patient health, but this will not be achieved unless we 
build sustainable models together that work for all.
Clinical Study Data Request (CSDR) is a 
consortium of 13 international pharma-
ceutical companies (GSK, Astellas Pharma, 
Bayer, Chugai, Eisai, Novartis, ONO, Roche, 
Sanofi, Sunovion, Shionogi Inc, UCB and 
ViiV) and four academic research funders 
(The Wellcome Trust, The Bill & Melinda 
Gates Foundation, The UK Medical Research 
Council and Cancer Research UK).1 It was 
launched in 2013 and currently lists anony-
mised patient data from 3374 studies on the 
platform, including 10 studies from academic 
funders. The mandate is to reduce the barriers 
to access and reuse data, thereby facilitating 
data sharing in an equitable, transparent and 
independent manner.
Clinical trial data can be used beyond the 
original purpose for which it was generated, 
including for analysis of new hypotheses, 
avoiding duplicative research, ensuring 
reproducibility and to drive scientific 
research and innovations to improve patient 
care. As the value of clinical data is now widely 
recognised, many global initiatives actively 
promote and enable sharing of research data 
and most funders mandate researchers to 
plan for sharing their data.2–4 The European 
Medicines Agency and the National Insti-
tutes of Health have requirements in place 
for data disclosure and clinical trial transpar-
ency.5 Trial participants’ confidentiality and 
privacy need to be protected and the terms of 
consent to participate in research respected. 
Managed access systems can help with this, 
including an Independent Review Panel’s 
(IRP) review of all requests for data access 
and having data sharing agreements in place 
that place appropriate restrictions on data 
usage, though it should be recognised that 
these systems add time to the process from 
application to data access.
CSDR’s system allows researchers to 
request access to anonymised global clin-
ical trial data from multiple studies and 
sponsors. All data requests that pass initial 
administrative and data availability checks 
are reviewed by an IRP, the secretariat for 
which is provided by Wellcome. Once access 
is granted, nearly all CSDR members restrict 
data access to a secure online analysis envi-
ronment that they say ensures patient privacy 
while maintaining the utility of the data for 
secondary analysis. This system can limit 
the merging of data from other non-CSDR 
sources and the range of software available 
for researchers. Free access to data is usually 
granted for 12 months, with the possibility of 
extension, and CSDR requires researchers to 
report on findings, which are then listed on 
the website.
Protected by copyright.
 o
n
 Septem
ber 4, 2019 at Erasm
us M
edical / X51 4300.7802.430.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2019-032334 on 21 August 2019. Downloaded from 
2 Kochhar S, et al. BMJ Open 2019;9:e032334. doi:10.1136/bmjopen-2019-032334
Open access 
Figure 1 The progress of research proposals through the 
CSDR system. Of the 471 proposals submitted to CSDR 
(2014–January 2019), 123 were withdrawn by the requestor at 
some point through the process. The IRP rejected 55, but 34 
of these went on to resubmit revised proposals following IRP 
suggestions for improvements. Of the 222 that gained access 
to the data (in progress and completed) 41 have published at 
least one paper, with another 28 expecting to publish soon. 
CSDR, Clinical Study Data Request; IRP, Independent Review 
Panel.
CsDr metriCs
From 2014 to the end of January 2019, there were a total 
of 471 research proposals (RPs) submitted to CSDR. Of 
these, 364 met initial administrative and feasibility checks 
from the sponsors. Although the sponsors have a right 
to veto a request on the grounds of potential conflict 
of interest or competitive risk, this veto has never been 
used. In reviewing applications, the IRP default position 
is to provide access, and they have approved 291 (84% 
of those considered) and rejected 55. Thirty-four of the 
rejected RPs were subsequently revised and resubmitted. 
The remaining RPs are either still in process, withdrawn 
or no response has been received from the researchers 
(figure 1). The most common reasons for rejection were 
unclear or unsuitable statistical methods (eg, a lack of 
detail on: the exact meta-analytic method proposed, how 
models will be validated or how data from different study 
designs and sites can be combined), too technical lay 
summaries and insufficient information presented.
Overall, the annual number of RPs submitted has 
remained fairly static with 70 submitted in 2014, 96 (2015), 
92 (2016), 85 (2017) and 97 (2018). Researchers at insti-
tutions in over 30 different countries have submitted RPs, 
although 168 RPs have been from researchers based in 
the USA (35%) and very few have been submitted from 
researchers based in low-income and middle-income 
countries.
From January 2014, it became possible to request data 
from multiple sponsors and 17% (73/427) of RPs have 
requested data from more than one sponsor. However, 
the median number of studies per RP is 2 (1–5, 25th–
75th percentile), with only a handful of RPs requesting a 
large number of studies (the biggest request involved 192 
studies and 11 sponsors).
Of the >4000 studies ever listed on CSDR (over the years, 
studies have been listed and then removed when sponsors 
leave the platform), 1457 have been requested. Interest-
ingly, the majority (1157, 79%) have been requested only 
once or twice, but four have been requested more than 10 
times (NCT00153062, NCT00268216 and NCT00410384, 
which was always requested along with NCT00424476).
Of the 90 research teams that completed their analysis 
by January 2018, 41 (45%) have at least one publication, 
28 (31%) are publishing soon and the remaining 21 have 
either not published or not responded to reminders from 
CSDR. Although these numbers appear encouraging in 
terms of converting access to data into publications of 
new findings, of concern are the 54 RPs (24%) whose 
researchers were granted access but did not log into 
the analysis environment. It is puzzling why this would 
happen, given the significant investment on both the part 
of the sponsors and the researchers in getting the RPs 
to this point in the process. CSDR is planning to contact 
those researchers to understand their constraints and 
challenges.
LessOns LeArneD
From an IRP’s perspective, the lessons learnt from the 
CSDR experience include the following:
CSDR is a valuable resource of data from pharmaceu-
tical companies and academic research funders that 
is available for free for researchers. However, it is an 
expensive and resource-intensive task for trial sponsors 
to provide access to data through this managed access 
model when it involves secure analysis environments 
with licenced software, and this may challenge the long-
term sustainability of such a platform. With over 50% of 
studies never being requested, perhaps more resources 
need to be focused on driving the reuse of data. Research 
agendas informed by the whole community could drive 
the sharing and reuse of data for specific questions that 
are of the highest priority for health practice, although 
this does limit the resource to current thinking on what 
is most interesting. The research programmes of the 
Project Data Sphere cancer data sharing platform is an 
example of how this model could work.6
Pharmaceutical companies and academic funders 
should pool resources to strengthen and sustainably 
support data sharing infrastructure and to develop and 
implement harmonised principles, standards and best 
practices.7 The portal cost for the sharing of data should 
not be prohibitive for new data contributors.
It is important that there is a transparent system in place 
for data access decisions to maintain equity for all those 
that want to reuse data. There is a minimum requirement 
for sufficient statistical skills within the team requesting 
access to carry out the research proposed, and this may 
mean there is currently a bias towards higher resourced 
settings. Funders should consider supporting capacity 
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building efforts to increase the data analysis expertise of 
teams based in low-income and middle-income settings.
The IRP and the secretariat support provided by Well-
come have been critical to ensuring a trusted and inde-
pendent managed access system. Having an experienced 
and multidisciplinary IRP with expertise in ethics, statis-
tics, epidemiology, clinical research and a lay member has 
helped to ensure that feedback is provided to the data 
requesters, including suggestions for how to improve 
proposals with respect to the analysis methods and the 
clarity of how the research will benefit patients and to 
ensure all proposals receive consistent review. The IRP’s 
perspective is to encourage and facilitate data sharing 
(unless there are significant reasons not to do so). The 
respected quality of the IRP service has been demon-
strated by a newer data sharing platform (Vivli), launched 
in 2018, requesting the Wellcome IRP also be available 
for data contributors to their system. The IRP accepted 
this request and has already considered several proposals 
through this platform too, applying the same criteria as 
for CSDR.
It would be helpful if consent for clinical research 
could, as far as possible, include provision for reuse of 
their anonymised data beyond the original study.7 In the 
absence of specific guidance, institutional ethics commit-
tees should also adopt consistent policies for the need 
(or not) for ethics review for secondary use of anony-
mised data. This would clarify if ethics review is needed 
(or not), increase the amount of data available for reuse 
and decrease the time to access the data. Data generators 
might also feel reassured about using a file transfer model 
rather than restricting to the use of a controlled analysis 
environment.
The data access process should be easily discover-
able with transparent metrics for potential data users. A 
common data sharing agreement should be available for 
all the data providers, and once researchers from an insti-
tution have signed the agreement, it should be applicable 
for other researchers from that institution (to decrease 
the time often taken by institutions negotiating changes 
to the agreement).
Merging multiple datasets is critical for finding small or 
subpopulation effects that could not have been observed 
from any individual trial alone. However, the resource 
involved in pooling, or even finding suitable data can 
be prohibitive if there are no common standards used. 
CSDR industry sponsors mostly all use Clinical Data 
Interchange Standards Consortium standards,8 but the 
academic research community does not currently employ 
agreed standards, which is barrier to truly accessible and 
interoperable data.
The analysis environment must be easily usable by 
the researchers (including for merging multiple data-
sets and statistical analysis) and not be expensive for 
the data providers. Increasing efficiency in the process 
to ensure that data access happens as soon as possible 
benefits the researchers (currently, the median time 
from submission to data access is 190 days in CSDR). 
It is critical that researchers that get access to the data 
report their results in a timely manner (eg, within 
6 months of completion of data access), so that it helps 
to move the research field forward and reduce research 
waste. This should be a requirement in the data sharing 
agreement.
Some pharmaceutical companies had the fear that 
data might be accessed for competitive advantage or to 
disprove trial results. In all the years of CSDR, these fears 
have been unfounded. This should encourage other 
pharmaceutical companies to share their data.
Sharing of data on CSDR by academic funders is low 
and barriers to using the strength of the platform should 
be identified and addressed. The four academic funders 
who are CSDR members are currently gathering feedback 
from their grantees about the challenges and support 
they need to share clinical data. Other academic funders 
could encourage their grant holders to start sharing their 
clinical research data using this or similar platforms.
COnCLusiOns
Sharing of anonymised, patient-level clinical trial data 
through platforms like CSDR advances research and 
innovation. International pharmaceutical companies and 
academic funders are making their data available for free 
to the research community in a transparent and equitable 
manner. Challenges still remain to speed up the process 
and enable data value to be maximised. Researchers need 
incentives to share, such as citation of their data (which 
requires unique identifiers to be embedded) being 
recognised by funders and institutions in decision making. 
The costs of sharing and reuse need to decrease, which 
will be helped by adoption of standards in the creation 
of data, and reduced use of controlled analysis environ-
ments. Guidance from professional bodies addressing, 
for example, consent issues and common data sharing 
agreements would help promote data sharing. Despite 
these challenges great advances have already been made, 
and models developed that mean there are more clinical 
trial data available for reuse than ever before. We hope 
this field will continue to develop to meet the needs of all 
stakeholders.
Contributors All authors were involved in the conception, drafting and revision of 
the article.
Funding The authors have not declared a specific grant for this research from any 
funding agency in the public, commercial or not-for-profit sectors.
Competing interests GSH is the secretariat for the Independent Review Panel and 
all other authors are members of the IRP.
Patient consent for publication Not required.
Provenance and peer review Not commissioned; externally peer reviewed.
Open access This is an open access article distributed in accordance with the 
Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which 
permits others to distribute, remix, adapt, build upon this work non-commercially, 
and license their derivative works on different terms, provided the original work is 
properly cited, appropriate credit is given, any changes made indicated, and the use 
is non-commercial. See: http:// creativecommons. org/ licenses/ by- nc/ 4. 0/.
Protected by copyright.
 o
n
 Septem
ber 4, 2019 at Erasm
us M
edical / X51 4300.7802.430.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2019-032334 on 21 August 2019. Downloaded from 
4 Kochhar S, et al. BMJ Open 2019;9:e032334. doi:10.1136/bmjopen-2019-032334
Open access 
reFerenCes
 1. Clinical study data request. Available: https://www. clin ical stud ydat 
arequest. com/ Default. aspx [Accessed 20 Jul 2019].
 2. Institute of Medicine. Sharing clinical trial data maximizing benefits, 
minimizing risk 2015.
 3. Kiley R, Peatfield T, Hansen J, et al. Data sharing from clinical trials - a 
research funder's perspective. N Engl J Med 2017;377:1990–2.
 4. Taichman DB, Backus J, Baethge C, et al. Sharing clinical trial data--a 
proposal from the international committee of medical journal editors. 
N Engl J Med 2016;374:384–6.
 5. National Institute for health sharing policies. Available: https:// grants. 
nih. gov/ policy/ sharing. htm [Accessed 20 Jul 2019].
 6. Project data sphere. Available: https://www. projectdatasphere. org/ 
projectdatasphere/ html/ home [Accessed 20 Jul 2019].
 7. Burton PR, Banner N, Elliot MJ, et al. Policies and strategies to 
facilitate secondary use of research data in the health sciences. Int J 
Epidemiol 2017;46:1729–33.
 8. CDISC standards in the clinical research process. Available: https://
www. cdisc. org/ standards [Accessed 20 Jul 19].
Protected by copyright.
 o
n
 Septem
ber 4, 2019 at Erasm
us M
edical / X51 4300.7802.430.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2019-032334 on 21 August 2019. Downloaded from 
